The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRtw Biotech Regulatory News (RTW)

Share Price Information for Rtw Biotech (RTW)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.43
Bid: 1.43
Ask: 1.45
Change: 0.00 (0.00%)
Spread: 0.02 (1.399%)
Open: 1.42
High: 1.43
Low: 1.42
Prev. Close: 1.43
RTW Live PriceLast checked at -
RTW Venture is an Investment Trust

To achieve positive absolute performance and superior long-term capital appreciation, with a focus on forming, building, and supporting world-class life sciences, biopharmaceutical and medical technology companies.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Edison issues review on RTW Venture Fund (RTW)

20 Oct 2022 07:00

RNS Number : 4363D
RTW Venture Fund Limited
20 October 2022
 

London, UK, 20 October 2022

 

Edison issues review on RTW Venture Fund (RTW)

RTW Venture Fund (RTWVF) is managed by global healthcare specialist RTW Investments (RTW) that has offices in New York, London and Shanghai. It offers a broad range of financing options from business formations through to listed biotech and medtech companies. RTW's managers are hopeful that the performance of biotech stocks will continue to improve following a significant sell off, particularly in smaller-cap stocks, between February 2021 and May 2022. Biotech industry fundamentals and valuations are attractive, so investors with a longer-term perspective that can look through the current challenging macroeconomic backdrop may benefit from an allocation to the sector.

 

RTWVF is trading at a 20.1% discount to NAV, which is a considerably lower valuation than the average 4.1% premium since the fund was launched in October 2019. There is potential for a narrower discount if investor sentiment towards biotech stocks continues to improve and RTWVF is able to build on its longer-term positive performance record.

Click here to view the full report or here to sign up to receive research as it is published.

 

All reports published by Edison are available to download free of charge from its website

www.edisongroup.com

About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached - across institutions, family offices, wealth managers and retail investors - Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings.

Having been the first in-market 17 years ago, Edison now has more than 100 analysts covering every economic sector. Headquartered in London, Edison also has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in Athens, Johannesburg and Sydney.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information, please contact Edison:

Mel Jenner +44 (0)20 3077 5700 investmenttrusts@edisongroup.com

Learn more at www.edisongroup.com and connect with Edison on: 

LinkedIn www.linkedin.com/company/edison-group-/

Twitter www.twitter.com/Edison_Inv_Res

YouTube www.youtube.com/edisonitv

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRABBBDGCGBDGDC
Date   Source Headline
18th Jun 20214:35 pmRNSPrice Monitoring Extension
16th Jun 20217:00 amRNSIssue of Equity
15th Jun 202112:05 pmRNSNew Investment in Umoja Biopharma
14th Jun 20212:32 pmRNSAnnouncement of Share Issuance
14th Jun 20217:00 amRNSNet Asset Value(s)
9th Jun 202112:05 pmRNSNew Investment in Alcyone Therapeutics
2nd Jun 20217:00 amRNSNotice of AGM
26th May 20211:05 pmRNSAdditional Investment in Portfolio Company
20th May 20218:05 amRNSNew Investment in Numab Therapeutics
14th May 20217:00 amRNSNet Asset Value(s)
29th Apr 20217:00 amRNSAnnual Financial Report
28th Apr 20217:00 amRNSQuarterly Update
19th Apr 20217:00 amRNSPortfolio Company Update: Biomea IPO
15th Apr 20217:00 amRNSNet Asset Value(s)
1st Apr 20217:05 amRNSTotal Voting Rights
1st Apr 20217:00 amRNSNotice of Annual Report
30th Mar 20211:00 pmRNSNew Investment in Pyxis Oncology
17th Mar 20217:00 amRNSIssue of Equity
15th Mar 20217:01 amRNSAnnouncement of Share Issuance
15th Mar 20217:00 amRNSPortfolio Company Update: Prometheus IPO
12th Mar 202112:30 pmRNSNew Investment in Monte Rosa Therapeutics
12th Mar 20217:00 amRNSNet Asset Value(s)
9th Mar 20211:45 pmRNSNew Investment in Ventyx Biosciences
9th Mar 202112:45 pmRNSNew Investment in Visus Therapeutics
1st Mar 20211:00 pmRNSNew Investment in Tenaya Therapeutics
1st Mar 20217:00 amRNSTotal Voting Rights
26th Feb 20211:15 pmRNSNew Investment in Artiva Biotherapeutics
18th Feb 20217:00 amRNSIssue of Equity
15th Feb 20214:10 pmRNSAnnouncement of Share Issuance
15th Feb 20217:00 amRNSNet Asset Value(s)
8th Feb 20217:00 amRNSPortfolio Company Update: Immunocore IPO
5th Feb 20217:00 amRNSPortfolio Company Update: Landos IPO
1st Feb 20217:00 amRNSChange of Administrator and Company Secretary
1st Feb 20217:00 amRNSTotal Voting Rights
25th Jan 202110:04 amRNSDirector/PDMR Shareholding
22nd Jan 20217:00 amRNSQuarterly Update
19th Jan 20216:11 pmRNSIssue of Equity
15th Jan 20213:39 pmRNSAnnouncement of Share Issuance
15th Jan 20217:00 amRNSNet Asset Value
11th Jan 202112:22 pmRNSAdditional Investment in Portfolio Company
6th Jan 20213:30 pmRNSNew Investment in Biomea Fusion
29th Dec 202010:16 amRNSDirector/PDMR Shareholding
24th Dec 20208:35 amRNSDirector/PDMR Shareholding
23rd Dec 20209:07 amRNSDirector/PDMR Shareholding
14th Dec 20207:00 amRNSNet Asset Value(s)
10th Dec 20207:00 amRNSTransformational Update from Largest Holding
8th Dec 20208:03 amRNSNew Investment in Nuance Pharma
1st Dec 20207:00 amRNSTotal Voting Rights
16th Nov 20205:59 pmRNSIssue of Equity
13th Nov 20206:22 pmRNSAnnouncement of Share Issuance

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.